GlassScriptPhysician profile
Janet Maldonado
NPI 1518099977
$6,482.03
in general payments reported to CMS, 2019-2025
28 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $517 · 2021: $677 · 2022: $905 · 2023: $773 · 2024: $653 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.12 |
| Education | $229.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $946.06 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $770.76 | 2019-2025 | |
| Lilly USA, LLC | $652.89 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $496.85 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $466.69 | 2019-2024 | |
| Pfizer INC. | $462.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $449.95 | 2019-2024 | Dupixent |
| Incyte Corporation | $419.75 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $251.69 | 2019-2025 | Anzupgo, Adbry |
| Amgen INC. | $246.69 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $166.54 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.12 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Sun Pharmaceutical Industries INC. | $165.10 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $141.28 | 2022-2024 | Vtama |
| Organon LLC | $116.41 | 2025 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $92.23 | 2024-2025 | Zoryve |
| Biofrontera INC. | $59.77 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $59.63 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $56.35 | 2024 | Sotyktu |
| Almirall LLC | $55.37 | 2019-2021 | |
| Allergan, INC. | $52.59 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $40.33 | 2020 | |
| Epi Health, LLC | $36.92 | 2019 | |
| Dusa Pharmaceuticals, INC. | $31.20 | 2019 | |
| Botanix Sb INC | $23.28 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2022 | |
| Strata Skin Sciences, INC. | $18.51 | 2021 | |
| Dermira, INC. | $15.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.